PolyPid Ltd. — FY2022 Form 20-F
Reporting period: Fiscal year ended December 31, 2022; this is an annual report, not a standalone fourth-quarter filing. Financial statements are audited and prepared under U.S. GAAP. PolyPid is a clinical-stage biopharmaceutical company developing localized, prolonged-release therapies using its PLEX technology. It had no approved products and no product-sale revenue.
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Product-sale revenue | None | None |
| Research and development, net | $28.0 million | $30.6 million |
| Marketing and business development | $2.9 million | $3.0 million |
| General and administrative | $8.0 million | $9.6 million |
| Operating loss | $38.9 million | $43.1 million |
| Net loss | $39.6 million | $42.6 million |
| Basic and diluted loss per share | $2.04 | $2.28 |
| Net cash used in operating activities | $34.3 million | $32.4 million |
At year-end, cash and cash equivalents were $8.6 million, short-term deposits $4.0 million, and restricted cash $0.5 million. Total assets were $26.0 million, shareholders’ equity $5.8 million, and debt $11.6 million ($4.0 million current and $7.6 million long-term). No product revenue or meaningful operating margin was reported. The Advanz upfront license payment was recorded as deferred revenue; no revenue was recognized under that agreement in 2022.
Cash, cash equivalents and short-term deposits totaled $12.6 million at December 31, 2022. Management said available cash was expected to fund expenses and capital needs well into the first quarter of 2024, but also said additional capital would be needed to complete D-PLEX 100’s clinical and regulatory program. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Operating cash use increased year over year; investing cash inflow chiefly reflected release of deposits, while financing inflow included Kreos borrowing and ATM share sales.
Material changes and business developments
- Operating loss narrowed by about $4.3 million and net loss by about $3.0 million versus 2021, chiefly reflecting lower R&D and general and administrative expenses. Financial results included $1.0 million of loan-related expense; financial income of $0.5 million in 2021 became a $0.5 million expense in 2022.
- SHIELD I Phase 3 did not meet its primary endpoint in the full intent-to-treat population: D-PLEX 100 plus standard of care reduced the endpoint by 23% versus standard of care alone, but the result was not statistically significant (p=0.1520). A pre-specified subgroup with incisions over 20 cm showed a 54% reduction (p=0.0032); this subgroup result does not change the overall trial’s failure to meet its primary endpoint.
- After discussions in January 2023, the FDA acknowledged SHIELD I could provide supportive evidence for the large-incision population and recommended an additional study. SHIELD II could potentially serve that role. The filing expected recruitment to resume in Q2 2023, with about 550 additional patients, an interim analysis after approximately 400 patients completed 30-day follow-up, and top-line results in mid-2024.
- In October 2022, PolyPid announced a 20% workforce reduction. Year-end headcount was 57 full-time and 3 part-time employees, down from 75 full-time and 4 part-time in 2021.
Outlook, risks and unusual items
- Management expected continuing losses and cash outflows, with no product-sale revenue anticipated for at least the next few years. The company said further financing would be required; failure to raise it could delay, reduce or end development programs.
- In March 2023, the Kreos loan was amended: 70% of remaining principal and interest repayments were deferred to August 2024–May 2026; the rate rose to 10%, with restructuring fees and a potential $1.5–$3.0 million claw-back if qualifying financing or partnership proceeds are received. The loan is secured by equipment, intellectual property and subsidiary shares.
- Subsequent to year-end, PolyPid raised gross proceeds of approximately $7.1 million in a March 31, 2023 public offering and approximately $4.35 million through a concurrent private placement of pre-funded warrants. It also reported $2.19 million net proceeds from January 2023 ATM sales. These transactions increased potential dilution; they do not remove the filing’s stated financing and execution risks.
- Advanz received exclusive D-PLEX 100 commercialization rights in the EEA and UK. The agreement included a €2.5 million upfront payment, up to €23 million in development milestones, up to €87 million in sales milestones, and double-digit royalties reaching the mid-twenties; future amounts are contingent, not assured.
- Other significant risks include dependence on SHIELD II’s enrollment and results, regulatory uncertainty after SHIELD I, manufacturing validation and supplier dependence, reimbursement and market acceptance, intellectual-property protection, and political or security disruptions in Israel. The company received a Nasdaq minimum-bid-price deficiency notice in December 2022, with a June 5, 2023 compliance deadline stated in the filing.
- OncoPLEX remained preclinical; the company was finalizing manufacturing and CMC processes and had not begun clinical development. EMA centralized-procedure eligibility for D-PLEX 100 is not marketing approval.
Investor verification priorities
- Verify SHIELD II enrollment, interim-analysis terms, final results and subsequent FDA feedback; assess the full-population SHIELD I result separately from subgroup findings.
- Check current cash, cash runway and financing needs after the 2023 ATM and offerings, including dilution from shares and pre-funded warrants.
- Review Kreos’s amended repayment schedule, collateral, fees and claw-back triggers, and confirm outstanding debt balances.
- Confirm the status of Nasdaq listing compliance and any subsequent regulatory or commercial developments involving D-PLEX 100 and Advanz.
- Assess whether manufacturing validation, supply arrangements, and any required regulatory inspections support the projected development timeline.